AI-generated summary
The authors studied extracellular vesicles from microglia treated with 850 nm light (photobiomodulation) to deliver UFL1, a protein that stabilizes p53, in cell and rat models of spinal cord injury. They report that these vesicles promoted neuronal differentiation in vitro and improved immune environment, axonal regeneration and hindlimb motor recovery in rats, effects that were reduced when UFL1 or p53 was blocked. The findings come from preclinical cell and animal work only.
- Who or what was studied
- Neural stem cells in vitro and a rat model of spinal cord injury
- Wavelengths
- 850 nm
- Limits stated in the abstract
- The study is limited to cell culture and a rat model, and the abstract does not report human data.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Spinal cord injury (SCI) often results in permanent motor dysfunction, and no approved therapy effectively promotes nerve regeneration. We show that engineered extracellular vesicles (EVs) from photobiomodulation (PBM)-treated microglia, delivering UFL1 (the sole E3 ligase of the UFMylation system), significantly enhance neural repair after SCI. PBM (850 nm, 2.0 J/cm2) promoted microglial M2 polarization and suppressed M1. We isolated PBM-EVs and identified UFL1 as the key effector via proteomic analysis. Mechanistically, UFL1 competes with MDM2 for p53 binding, inhibiting p53 ubiquitination and degradation, thus stabilizing p53 and activating its signaling. In vitro, PBM-EV-delivered UFL1 protected neural stem cells from inflammation-induced apoptosis and promoted neuronal differentiation; these effects were markedly attenuated by UFL1 knockdown or p53 inhibition. In a rat SCI model, PBM-EVs delivering UFL1 significantly improved the local immune microenvironment, promoted M2 microglial polarization, reduced glial scar formation, and enhanced axonal regeneration and hindlimb motor recovery. Pharmacological p53 inhibition with PFT-α or UFL1 knockdown in donor EVs substantially diminished these therapeutic effects in vivo, confirming the central role of the UFL1/p53 axis. Overall, PBM-EVs deliver UFL1 to activate p53 signaling, synergistically regulating immunity and neural differentiation to promote functional recovery, highlighting the UFL1/p53 axis as a therapeutic target for SCI.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
- Energy density (fluence)
- 2.0 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.